Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen loses its R&D chief to a small biotech

This article was originally published in Scrip

Executive Summary

Douglas Williams, who has been Biogen's executive vice president of R&D since January 2011, is leaving the company to become CEO of an as-yet unnamed biotechnology start-up. He will be the first member of a new organization with potential in cancer diagnostics and therapy, according to Biogen. Responsibility for Biogen's R&D will be assumed by Alfred Sandrock, chief medical officer, and Spyros Artavanis-Tsakonas, chief scientific officer. "While I am sad to leave Biogen I am excited about the opportunity to follow a real passion of mine," said Dr Williams. There has been a spate of recent high-profile departures from pharma companies to head up small biotechs.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC029208

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel